Skip to main content
main-content

Heart failure

News

19-11-2019 | Heart failure | Highlight | News

Dapagliflozin improves life quality for people with heart failure

Dapagliflozin treatment significantly improves self-reported symptoms, physical function, and quality of life in people who have heart failure with reduced ejection fraction, report the DAPA-HF investigators.

19-11-2019 | Heart failure | News

Support for add-on dapagliflozin use in HF patients of all ages

A post-hoc analysis of data from the DAPA-HF trial indicates that the sodium-glucose cotransporter 2 inhibitor dapagliflozin has consistent efficacy and safety profiles among people with heart failure and reduced ejection fraction across a range of age categories.

28-10-2019 | Metformin | News

Long-term metformin use may reduce heart failure risk

Study results suggest that prolonged use of metformin by people with type 2 diabetes may reduce their risk for being hospitalized with heart failure.

Read more

Opinion

14-11-2018 | Cardiovascular outcomes | Editorial | Article

What have I learned from cardiovascular outcome trials?

Endocrinologist Sanjay Kalra considers the impact that cardiovascular outcome trials have had on the standard of diabetes care and questions what else they might accomplish in the future.

13-02-2018 | Older adults | Editorial | Article

Does setting treatment targets risk the overtreatment of type 2 diabetes in older patients?

The drive to achieve lower HbA1c targets in older patients is not without concern or risk. Our UK Board address concerns highlighted by recent trials and discuss whether current guidelines do enough to mitigate the risks of overtreatment.

22-11-2017 | Cardiovascular disorders | Editorial | Article

Diabetes in special situations: Sodium-glucose co-transporter-2 inhibitors in acute coronary syndrome

Editorial Board member Sanjay Kalra presents a pragmatic approach to the use of sodium-glucose co-transporter-2 inhibitors in patients affected by acute coronary syndromes.

In depth

16-11-2018 | Dapagliflozin | Video | Article

Researcher comment: DECLARE-TIMI 58

DECLARE-TIMI 58 steering committee member John Wilding talks us through the trial's findings (5:49).

10-11-2018 | Dapagliflozin | Video | Article

Expert commentary: DECLARE-TIMI 58

Miles Fisher talks to medwireNews about the results of the dapagliflozin cardiovascular outcomes trial DECLARE-TIMI 58.

Journal articles and book chapters

08-11-2018 | Cardiovascular disorders | Review | Article

The evolving role of the cardiologist in the management of type 2 diabetes

Chilton RJ et al. Curr Diab Rep 2018; 18: 144. doi: 10.1007/s11892-018-1114-1

23-06-2018 | Cardiovascular outcomes | Review | Article

Cardiovascular outcome studies in type 2 diabetes: Comparison between SGLT2 inhibitors and GLP-1 receptor agonists

Scheen AJ. Diabetes Res Clin Prac 2018; 143: 88–100. doi: 10.1016/j.diabres.2018.06.008

22-06-2018 | Hypertension | Review | Article

The optimal blood pressure target in diabetes mellitus: A quest coming to an end?

Papadopoulou E et al. J Hum Hypertens 2018. doi: 10.1038/s41371-018-0079-5

Image Credits